- Home
- PLX vs NGEN Comparison
PLX vs NGEN Comparison
Compare PLX & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLX | NGEN |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.4M | 197.5M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLX | NGEN |
|---|---|---|
| Price | $2.20 | $2.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $18.00 |
| AVG Volume (30 Days) | 569.2K | ★ 1.5M |
| Earning Date | 05-12-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $36.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.18 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.34 | $1.70 |
| 52 Week High | $3.19 | $5.93 |
Technical Indicators
Market Signals| Indicator | PLX | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.05 | 44.13 |
| Support Level | $2.03 | $1.70 |
| Resistance Level | $2.42 | $4.44 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 98.93 | 88.52 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.